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Summary
Objective: The Sox9 transcription factor has emerged as an important determinant of chondrocyte differentiation, including the regulation of
type II collagen (Col2) and aggrecan gene expression. We sought to identify a human cell line model that conserves the Sox9 regulatory
pathways identified in the mouse.
Design: The SW1353 chondrosarcoma cell line was considered to be a candidate for Sox9 studies. The activity of a Sox9 regulated Col2a1
enhancer reporter gene was analyzed in response to treating cells with known regulators of murine Sox9 expression/activity. The effect of
treatment on expression of the endogenous Sox9 gene was analyzed by real-time PCR and Western blot.
Results: Col2 enhancer activity was stimulated by fibroblast growth factors (FGF-1 and -2) and repressed by inflammatory cytokines (IL-1β
and TNFα) in SW1353 cells. These effects correlated with changes in Sox9 mRNA and protein levels. In addition, FGF-9 was shown to
stimulate enhancer activity and Sox9 expression. Cotreatment studies demonstrated that FGFs functionally antagonize the cytokine-
mediated repression of Sox9 expression and Col2 enhancer activity.
Conclusions: SW1353 cells represent a useful human cell model as they conserve many Sox9 signaling pathways previously demonstrated
in mouse chondrocytes. We identify FGF-9 as a particularly potent Sox9 agonist. The antagonism between FGFs and cytokines on Sox9
expression and Col2 enhancer activity suggests that Sox9 integrates the opposing activities of FGFs and cytokines. We also find that
SW1353 cells respond to very low doses of IL-1 with Col2 enhancer activation, while increasing doses lead to repression.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Common to osteoarthritis (OA) and rheumatoid arthritis
(RA) is the progressive destruction of articular cartilage.
This tissue provides the lubrication and compressibility
needed for joint function. Therefore, the loss of articular
cartilage results in increasing morbidity and pain. Articular
cartilage is composed of chondrocytes embedded in a
collagen- and proteoglycan-rich extracellular matrix. Thus,
the chondrocyte is central to understanding normal carti-
lage function as well as the arthritic and degenerative
diseases that affect it. Isolated primary chondrocytes have
little proliferative capacity and tend to de-differentiate
to fibroblast-like cells when cultured in vitro. Sources of
human cells for study, particularly from non-diseased tis-
sue, are extremely scarce for obvious reasons. Therefore,
much of our knowledge of chondrocyte biology is derived
from animal studies or their cultured tissues and cells.
The genetic studies from human subjects suffering from
severe skeletal abnormalities have contributed to our un-
derstanding of chondrocyte biology. Mutations leading to
the loss of function or expression of a single allele of
the human Sox9 gene were identified as the cause
of campomelic dysplasia1, a rare and severe skeletal
malformation syndrome2. Male patients also present with
XY sex reversal1 confirming the other major role of Sox9 in
development, male sex determination. Mice engineered to
express only one allele of the Sox9 gene (Sox9 +/−),
represent a near phenocopy of the human skeletal syn-
drome3, displaying hypoplasia of all cartilage primordia and
bones derived therefrom. Furthermore, mice derived by
chimerism of wild-type and Sox9−/− embryonic stem (ES)
cells showed that Sox9 is obligatory for cells to be incor-
porated into mesenchymal condensations destined to give
rise to cartilage structures4. The role of Sox9 in cartilage
determination is conserved across vertebrates, as ectopic
expression of Sox9 in developing chick embryos showed
the potential to trans-differentiate muscle and dermis into
cartilage5. Genetically modified mice having impaired or
enhanced Sox9 expression showed XY or XX sex reversal,
respectively6,7, and demonstrated the conservation of Sox9
in sex determination in mice and humans.
Sox9 is a member of a family of HMG-box proteins. This
family of proteins is unusual in that they bind to the minor
groove of DNA and cooperate with a protein partner(s) to
regulate gene expression (reviewed in reference 8). LSox5
and Sox6 appear to play overlapping roles in collaborating
with Sox9 to regulate the expression of chondrocyte target
genes including Col2a1 and aggrecan9,10. Sox9 also regu-
lates the ‘minor cartilage collagen’, Col11a2, by interactions
with HMG-like sites in both the promoter11 and within an
intronic enhancer12. Sox9 appears to integrate the many
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signaling pathways regulating the expression of cartilage
matrix proteins. These include signals that positively regu-
late the cartilage phenotype, such as FGFs, and BMP-2, as
well as parathyroid hormone related protein (PTHrP) in
prehypertrophic chondrocytes5,13,14. Inhibition of matrix ex-
pression by cytokines and retinoic acid also involves inhi-
bition of Sox915,16. Such studies have shown that Sox9
activity is regulated by both the level of Sox9 expression
and by post-translational modification17. Sox9 has been
termed the ‘Master Chondrogenic Transcription Factor’15.
Therefore, understanding Sox9 function in cartilage devel-
opment, tissue maintenance, and disease processes may
be important in considering strategies to halt cartilage
destruction, to maintain the chondrocyte phenotype, and to
induce repair. Here, we show that the human SW1353 cell
line conserves many of the Sox9 signaling pathways found
in primary murine chondrocytes. We make the novel obser-
vation that FGF-9 stimulates Sox9 expression and Col2
enhancer activity. In addition, we show that very low levels
of IL-1β actually stimulate expression of the Col2 enhancer,
while higher levels are inhibitory. This finding may have
relevance to the course of OA.
Materials and methods
SOX9 EXPRESSION PLASMID
To generate the human Sox9 mammalian expression
plasmid, total RNA from cultures of immortalized human
chondrocyte-like cells T/C-28a418 was purified using an
RNeasy kit with DNase treatment (Qiagen). The entire
1.5 kb coding region (GenBank database, accession no.
Z46629) was obtained by reverse transcription (Clontech
Advantage RT Kit) followed by PCR reaction (Roche
Expand High Fidelity PCR Kit) using primers: sense 5′-
CGGGATCCGCCACCATGAATCTCCTGGACCCCTTCAT
G-3′ and antisense 5′-CGGAATTCCTCAAGGTCGAGTG
AGCTGT-3′. The PCR product was subcloned into
pcDNA3.1 (+) (Invitrogen) and sequence verified.
CELL CULTURE
Tissue culture reagents were obtained from Invitrogen.
Recombinant FGF-1, -2, -7, and -9, IL-1β and TNFα were
obtained from R&D Systems. FGF-7 was supplied as a
glycerin solution containing bovine serum albumin (BSA);
all other growth factors and cytokines were supplied as
lyophilized samples containing BSA and reconstituted in
phosphate buffered saline (PBS) containing BSA according
to the manufacturer’s directions. SW1353 human chondro-
sarcoma cells (ATCC #HTB-94) were grown in DMEM
supplemented with 10% fetal bovine serum and 10 µg/ml
gentamicin. Subconfluent cells were passaged using
0.25% trypsin–EDTA, approximately 2 times per week by
dividing 1:10.
TRANSFECTION EXPERIMENTS
Experiments involving cotransfection of the Sox9 expres-
sion plasmid with the 48 bp Col2a1 luciferase reporter19
were performed with 2.6×104 SW1353 cells plated in
24-well dishes. The next day 0.25 µg of 48 bp Col2a1
reporter plasmid and a total of 0.25 µg of the Sox9 expres-
sion plasmid and/or pcDNA3.1 vector (Invitrogen) were
added to 1 µl of TransIt (PanVera) diluted into 100 µl of
OptiMEM. After 15–30 min, transfection complexes were
diluted to 1 ml with OptiMEM. Growth media were removed
and replaced with transfection mixture. Transfection com-
plexes were removed after 7 h and replaced with fresh
OptiMEM. Cells were harvested 48 h post-transfection and
luciferase activity measured using LucLite (Packard) and a
TopCount plate reader (Packard).
To assess the effects of growth factors and cytokines,
differences in well-to-well transfection efficiency were mini-
mized by performing bulk transfection of the 48 bp
Col2a119 luciferase reporter. Twenty-four hours prior to
transfection, 106 cells were plated in 10 ml of growth media
in 75 cm2 culture flasks. Each transfection consisted of
24 µl of TransIt (PanVera) diluted into 250 µl OptiMEM,
followed by the addition of 12 µg of plasmid DNA. After
15–30 min of incubation, growth media were removed from
the cells and replaced with the DNA–transfection reagent
complexes diluted to a final volume of 10 ml with OptiMEM.
After 7 h, each 75 cm2 flask of cells was subcultured into a
96-well plate using Cell Dissociation Solution (Sigma) and
OptiMEM. Twenty-four hours post-transfection, cells were
treated with FGFs or cytokines in OptiMEM. Vehicle treated
cells received an amount of PBS/BSA reconstitution buffer
that was equivalent to the highest amount included with any
FGF or cytokine treatment group (210 ng/ml BSA). Luci-
ferase activity was measured 24 h after treatment with
LucLite (Packard) or Bright-Glow (Promega) reagents.
HOECHST FLUOROCHROME ASSAY
Cells were plated into duplicate 96-well plates following
transfection and treated as described earlier. Media were
removed 24 h after treatment and cells were frozen in
100 µl of distilled water and lysed by a total of three
freeze–thaw cycles. DNA was stained with 100 µl of
20 µg/ml Hoechst 33528 dye in TNE (100 mM Tris, pH 7.0,
10 mM EDTA, 2 M NaCl), overnight at 37°C. Staining was
determined by reading fluorescence in a CytoFluor 4000
(Perspective Biosystems) with 360 nm excitation, 460 nm
emittance. Cell number was determined using a standard
curve.
WESTERN BLOTTING
Cell lysates were prepared from monolayer cultures
in 24-well dishes by the addition of SDS sample buffer
(Invitrogen). Equivalent amounts of lysate were sonicated
to shear genomic DNA, heat denatured in the presence
of 2-mercaptoethanol, and electrophoresed through SDS-
polyacrylamide (4–20 or 12%) gels in Tris–glycine buffer
(Invitrogen). Proteins were transferred to nitrocellulose
(Invitrogen) using a semi-dry apparatus (BioRad) and the
membrane blocked with Western blocking reagent (Roche).
Sox9 antibody20 was used at a 1:1000 dilution and GAPDH
antibody (Advanced Immunochemical) at 1:5000 dilution.
The secondary antibodies were goat anti-rabbit IgG and
rabbit anti-mouse IgG, conjugated to HRP (Pierce). Super
Signal Pico and Super Signal Femto ECL reagents (Pierce)
were used to develop blots prepared with overexpressed
or endogenous protein, respectively. Chemiluminescence
was imaged with a Lumi-Imager (Roche). Sox9 and
GAPDH band intensities were quantitated using the Lumi-
Analyst software 1D-gel application (Roche). Gel loading
differences were normalized to GAPDH values. Relative
Sox9 was calculated by dividing the normalized Sox9
values by the normalized untreated control lane value and
reported as fold change from the untreated control.
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TAQMAN RNA ANALYSIS
RNA was prepared from cells grown in 75 cm2 dishes
using RNeasy Kits with DNase treatment (Qiagen) accord-
ing to the manufacturer’s protocol, except that a second
application of DNase was included. cDNA was prepared
from 10 to 20 µl of RNA (1–4 µg) using random hexamer
primers and Taqman Reverse Transcription reagents
(Applied Biosystems). Taqman reactions were performed
with 8 µl cDNA and Universal PCR Master Mix (Applied
Biosystems), 900 nM PCR primers (forward primer 5′-
CACACAGCTCACTCGACCTTG-3′ and reverse primer
5′-TTCGGTTATTTTTAGGATCATCTCG-3′), and 200 nM
probe (6-carboxyfluorescein [FAM]-5′-CCCACGAAGGGC
GACGATGG-3′[TAMARA] 6-carboxytetramethylrhodamine).
Reactions (50 µl) were run using a Perkin–Elmer 5700
under standard conditions for 45 cycles. The data were
analyzed using GeneAmp5700 software (Applied Biosys-
tems), with threshold adjusted to a linear range for all
samples. The change in threshold cycle number (∆Ct) was
normalized to the GAPDH reference gene (commercial
probe and primers from Applied Biosystems), by subtract-
ing ∆CtGAPDH from ∆CtSox9. The effect of treatment (∆∆Ct)
was calculated by subtracting ∆Ctcontrol from ∆Cttreated.
Fold induction was determined by calculating 2∆∆Ct. Data
are reported as percent target cDNA in a treated sample
relative to untreated.
Results
COL2 ENHANCER ACTIVITY IS RESPONSIVE TO INCREASING
LEVELS OF SOX9
We began our studies by analyzing the activity of the
well-characterized 48 bp Col2a1 enhancer construct (48 bp
Col2a119) in transfected SW1353 cells. This reporter plas-
mid is constructed of five tandem repeats of the 48 bp
Col2a1 enhancer and encompasses the minimal se-
quence, including Sox9 binding sites, sufficient to direct
chondrocyte-specific expression in transgenic mice21.
While other transcription factors bind to this enhancer
fragment and help direct chondrocyte-specific gene
expression (e.g., LSox5 and Sox610), Sox9 binding is
necessary for full activity21.
SW1353 cells plated in 24-well dishes were transfected
with a constant amount of reporter (0.25 µg), with or without
increasing amounts of the Sox9 expression construct or
empty vector. Basal luciferase expression was detected
with the 48 bp Col2a1 reporter alone [Fig. 1(A), see inset].
The enhancer-less p89 control plasmid, containing the
same Col2a1 minimal promoter, was essentially inactive
(<5% activity, not shown). This suggests that SW1353 cells
constitutively express transcription factors that drive
Col2a1 enhancer activity. However, we determined that
Sox9 levels were limiting, as Col2a1 enhancer activity was
increased in a dose-dependent manner by cotransfection
with increasing amounts of the Sox9 expression plasmid
(Fig. 1A), and consistent with the results of cotransfection
experiments performed in murine chondrocytes and BALB/
3T3 cells20. At the highest concentration (0.25 µg), a slight
reduction of reporter activity was observed. This ‘squelch-
ing’ is often seen when transcription factors are expressed
at very high levels. Sox9 expression was confirmed by
preparing Western blots from cell extracts prepared
from duplicate transfections [Fig. 1(B)]. An immuno-
reactive band migrating with the 66 kDa marker was
observed with increasing intensity in cells transfected with
escalating amounts of Sox9 expression plasmid [Fig. 1(B)].
Expression of endogenous Sox9 was not detected in
untransfected SW1353 cells under these conditions, but
Fig. 1. Basal expression of the 48 bp Col2a1Luc enhancer reporter is
stimulated by coexpression of Sox9 in transiently transfected
SW1353 cells. Duplicate cultures of SW1353 cells were transfected
with a constant amount of the reporter plasmid DNA (0.25 µg) and
increasing amounts of Sox9 expression plasmid (0–0.25 µg) bal-
anced with pcDNA3.1 vector plasmid (0.25–0 µg). Cell extracts were
prepared from one of the duplicate cultures 24 h post-transfection and
luciferase activity measured (A). The Y-axis is expanded in the inset to
illustrate basal expression of the 48 bp Col2a1Luc reporter. Results
from a single experiment are shown and are representative of those
obtained in three independent studies. (B) Whole cell extracts were
made from the corresponding duplicate cultures depicted in (A) and
analyzed by Western blot using an antibody raised against Sox9.
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endogenous Sox9 expression was observed using con-
ditions of enhanced sensitivity to develop the blot (see Fig.
6 subsequently). These results suggest that endogenous
expression of Sox9 is limiting, although sufficient to direct
basal expression of the Col2a1 enhancer in SW1353
cells.
SW1353 CELLS ARE RESPONSIVE TO PRO-CHONDROGENIC FGFS
FGF receptor signaling has a profound effect on the
growth and differentiation of chondrocytes in vitro. How-
ever, the determination of physiologically relevant interac-
tions is made enormously complex since there are four
FGF receptors and 22 ligands in this family22. In murine
chondrocytes and immortal chondrocyte cell-lines (ATDC5
and C3H10T1/2), the 48 bp Col2a1 luciferase reporter is
induced by pro-chondrogenic factors including FGF-1 and
FGF-2, but not by FGF-714, which signals through the
epithelial-cell restricted FGFR2IIIb receptor. We analyzed
the responsiveness of SW1353 cells to these factors using
the 48 bp Col2a1 enhancer transfection assay. Addition of
FGF-1 or FGF-2 to the cultures increased the 48 bp en-
hancer reporter activity approximately 3-fold, whereas
FGF-7 expression had no effect [Fig. 2(A)]. Our results
show the conservation of FGF-1 and FGF-2 signaling
pathways in SW1353 cells.
We extended our studies to examine the effect of FGF-9
on enhancer activity. FGF-9 is a potent chondrogenic factor
and signals through FGFR3b and FGFR2c23. Mutations
that result in a constitutively active FGFR3 disturb the
balance between chondrocyte growth and differentiation24,
leading to skeletal malformations including achondroplasia,
hypochondroplasia, and thanatorphoric dysplasia25–27.
Furthermore, FGF-9 overexpression has been implicated in
chondromatosis, a rare disease characterized by cartilagi-
nous nodule formation of the synovium28. These studies
suggest a central role of FGF-9 in controlling the differen-
tiation of stem cells into chondrocytes. When added to
cultures of SW1353 cells that had been transfected with the
Col2a1 reporter, FGF-9 stimulated enhancer expression up
to 4-fold [Figs. 2(A) and 3]. This result suggests that
SW1353 cells express functional FGFR3b and/or FGFR2c
receptors.
FGF family members are mitogenic in some cell types22
and we considered the possibility that the effect of growth
factor on luciferase activity might be attributed to differ-
ences in the numbers of cells recovered at the time the
cultures were analyzed for luciferase activity. Therefore, we
determined the numbers of SW1353 cells following each
treatment in duplicate plates of transfected SW1353 cells
using a sensitive Hoechst dye DNA staining procedure. As
shown in Fig. 2B, after 24 h, similar numbers of cells were
recovered from the FGF treated cultures and vehicle con-
trols and argues against an indirect effect of FGFs on cell
number as that being responsible for increased Col2a1
activity.
PRO-INFLAMMATORY CYTOKINES REPRESS COL2 ENHANCER
ACTIVITY IN SW1353
IL-1β and TNFα were shown to repress Col2a1 enhancer
activity in primary murine chondrocytes. This activity is
NFκB-dependent and coincides with reduced Sox9 expres-
sion15. SW1353 cells express functional TNF and IL-1
receptors as these agents can stimulate the expression of
matrix metalloproteases (J.F.S. and L.B., data not shown
and reference 29). SW1353 cells were transfected with the
48 bp Col2a1 reporter and then treated with vehicle, TNFα
(10 ng/ml) or IL-1β (10 ng/ml) [Fig. 2(A)]. Enhancer driven
luciferase expression was reduced approximately 60% by
TNFα and 50% by IL-1β treatment. Similar numbers of cells
were recovered following cytokine treatment as determined
by DNA quantitation using Hoechst staining of duplicate
cultures [Fig. 2(B)].
Fig. 2. SW1353 cells respond to FGFs or cytokines with activation
or repression of the 48 bp Col2a1 enhancer reporter without
affecting cell numbers. To ensure equal transfection efficiency
among all samples, 75 cm2 flasks of SW1353 cells were transiently
transfected in bulk with the 48 bp Col2a1 enhancer luciferase
reporter. Seven hours post-transfection cells were dissociated,
pooled, and plated into duplicate 96-well plates. The next day cells
were treated with FGF-1 (200 ng/ml), FGF-2 (5.9 ng/ml), FGF-9
(200 ng/ml), FGF-7 (200 ng/ml), TNFα (10 ng/ml), or IL-1β (10 ng/
ml); these doses produced the maximal effect in dose–response
assays (data not shown). Luciferase activity was determined 24 h
post-treatment from one set of duplicate plates. Results represent
the mean and standard error from a representative study; in this
example 12 replicate wells for each treatment were used (A). The
relative light units have been normalized to percent vehicle control.
Similar results were obtained in three independent experiments.
(B) Cell counts recovered from the duplicate plates of cultured cells
in (A) were determined by DNA staining using Hoechst dye and a
standard curve prepared with known numbers of SW1353 cells.
The graph indicates the mean cell number and standard error for
each treatment group that comprises 12 replicates.
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CYTOKINE-MEDIATED INHIBITION OF ENHANCER EXPRESSION CAN
BE BLOCKED BY CO-TREATING CELLS WITH FGFS
As described earlier, SW1353 cells respond much like
murine chondrocytes to FGF-1 and FGF-2, and we extend
these findings to include FGF-9. Similarly, cytokines re-
press Col2a1 enhancer activity in SW1353 cells. These
results inspired us to address an important biological
question—can FGF co-treatment prevent the functional
consequences of IL-1β and TNFα on Sox9 activity and
Col2 enhancer expression? The results of this might influ-
ence the consideration of FGF strategies for the treatment
of joint damage resulting from inflammatory diseases. To
address this, SW1353 cells transfected with the Col2a1
reporter were cotreated with cytokine and with or without
FGF-1, FGF-2, or FGF-9 (Fig. 3). The results of this
experiment show that FGF-1, -2, and -9 can lead to a
significant attenuation of IL-1β- and TNFα-mediated re-
pression of Col2a1 enhancer activity. This novel result
indicates that pro-chondrogenic FGFs have the potential to
antagonize cytokine driven down-regulation of cartilage
matrix synthesis and suggests that Sox9 may play a role in
integrating these responses.
EXPRESSION OF THE COL2A1 ENHANCER REPORTER IS
STIMULATED BY THE PRESENCE OF LOW LEVELS OF IL-1β
An increase in the expression of two Sox9 regulated
genes, Col2a1 and aggrecan, has been observed in both
humans and dogs during the course of the osteoarthritic
disease30–32. Expression of both Col2 and aggrecan is
greatest in early to moderate disease and may reflect a
response by the chondrocytes to attempt repair of the
degenerating cartilage. Coincidentally, chondrocytes from
OA patients with early to moderate disease also show
expression of IL-1α and IL-1β and this expression declines
with the progression of the disease33. Thus, IL-1 expres-
sion is coincident with Col2 expression. IL-1 found in
osteoarthritic joint appears to be derived, at least in part,
from chondrocytes33 while macrophages produce large
amounts of IL-1 found in the rheumatoid joint34. This
suggests that IL-1 may not play the same role in the two
diseases.
To investigate this apparent paradox, we analyzed the
effect of varying IL-1β doses on the expression of the 48 bp
Col2a1 enhancer in transfected SW1353 cells. Surprisingly,
very low levels of IL-1β (0.1–1 pg/ml) stimulated enhancer
activity about ∼200% (Fig. 4); although the magnitude of
induction was modest, this response was consistently ob-
served. Col2a1 enhancer activity was decreased as the
concentration of IL-1β was increased above 1 pg/ml, with
maximal inhibition occurring between 20 and 100 pg/ml.
Therefore, SW1353 cells appear to respond to a dynamic
range of IL-1β levels with selective functional responses. In
addition, we found no evidence of a significant additive or
synergistic effect between low levels of IL-1β and FGFs in
cotreatment experiments (data not shown).
COL2 ENHANCER ACTIVITY CORRELATES WITH RELATIVE SOX9
MRNA AND PROTEIN EXPRESSION IN SW1353 CELLS
Previous studies showed that Col2a1 enhancer activity
correlates with Sox9 expression. FGF-2 stimulates and
cytokines repress the expression of Sox9 mRNA and
protein in primary mouse chondrocytes14,15, results that
point to Sox9 as being a key intermediate for regulating
expression of Col2 and aggrecan expression. Therefore,
we analyzed the effect of chondrocyte growth factors as
well as inflammatory cytokines on the expression of Sox9
mRNA in SW1353 cells using quantitative real-time PCR.
Cells were cultured and treated with growth factors or
cytokines as in Fig. 2A, and after 48 h cells were harvested
and RNA prepared. Expression of Sox9 mRNA was stimu-
lated approximately 1.5-fold by FGF-2 and 2-fold by FGF-1
or FGF-9, while TNFα and IL-1β decreased Sox9 expres-
sion to 60 and 47% of control, respectively (Fig. 5). Similar
results were obtained by analyzing Sox9 mRNA after 24 h
of treatment (data not shown). This suggests that Col2
enhancer activity is regulated, at least in part, by the level
of Sox9 expression; a finding that is consistent with studies
performed in mouse chondrocytes14,15.
We next examined whether the correlation between Col2
enhancer activity and Sox9 mRNA levels could be ex-
tended to the expression of endogenous Sox9 protein in
Fig. 3. FGFs block the down-regulation of Col2a1 enhancer activity
by cytokines. SW1353 cells were transfected, plated, and treated
as in Fig. 2A, except for the additional cotreatment of the indicated
FGF with IL-1β or TNFα. The relative light units have been
normalized to percent vehicle control, with vehicle equal to 100%.
Results correspond to the mean and standard error from triplicate
wells of a representative study. Similar results were obtained in
three independent experiments.
Fig. 4. The dynamic range of SW1353 biological response as a
function of IL-1β concentration. SW1353 cells were transiently
transfected with the 48 bp Col2a1Luc enhancer reporter and
treated with increasing concentrations of IL-1β. After 24 h media
were collected and luciferase activity measured as in Fig. 2A.
Results correspond to the mean and standard error from triplicate
wells of a representative study. Similar results were obtained in a
duplicate study.
Osteoarthritis and Cartilage Vol. 11, No. 4 237
SW1353 cells. Cells were treated for 24 h with the indicated
FGF, TNFα, IL-1β, or combination thereof, and cell extracts
prepared for Western blot analysis. In order to normalize for
any variability in the amount of total protein loaded, the
Sox9 antibodies were stripped from the blot and the blot
was probed with an antibody to GAPDH. Sox9 protein
expression was normalized to GAPDH and then all treat-
ments were compared relative to the vehicle. Expression of
endogenous Sox9 is observed in the vehicle lane (Fig. 6,
lane 1), although this requires more cell extract, greater
sensitivity chemiluminescence reagents, and a longer ex-
posure time when compared with that using overexpressed
protein (see Fig. 1). Cells treated with FGF-1, FGF-2, and
FGF-9 showed increased expression of Sox9 protein rang-
ing from 150 to 260% of vehicle (Fig. 6 lanes 2, 3 and 4,
respectively); while the levels of Sox9 protein were reduced
by 80 and 90% following 24 h of treatment with IL-1β and
TNFα, respectively (Fig. 6, lanes 5 and 6). At 48 h after
cytokine treatment, Sox9 protein expression was again
detectable but had not returned to untreated levels (data
not shown). Thus, FGFs increase and cytokines reduce the
mRNA, protein, and functional activity of endogenous
Sox9.
As shown earlier (Fig. 3), we found that FGFs could
antagonize the IL-1β and TNFα-mediated inhibition of the
Col2a1 enhancer activity in transfected SW1353 cells; a
finding that could be explained by several different mech-
anisms including a reduction in Sox9 expression, Sox9
activity, and/or by Sox9-independent cross-talk between
cytokine receptor and FGF receptor signaling pathways. To
address these possibilities, we began by determining the
effect of FGF-1, FGF-2, and FGF-9 on the IL-1β and
TNFα-mediated down-regulation of Sox9 protein expres-
sion. As shown in Fig. 6, FGF-1, FGF-2, and FGF-9
cotreatment with IL-1β or TNFα, resulted in the preser-
vation of Sox9 protein expression, albeit to different ex-
tents). This result is consistent with Col2a1 enhancer
activity in SW1353 cells in response to cotreatment with
FGF and IL-1β or TNFα, where the basal enhancer activity
was maintained by FGF cotreatment (see Fig. 3). Although
FGF-1 and -2 are active, FGF-9 appears to have the
greatest protective effect in both experiments, maintaining
Sox9 levels and Col2a1 reporter expression. Thus, FGF-9
may be particularly useful in counteracting joint damage
mediated by inflammatory cytokines.
Discussion
In this study, we demonstrate that SW1353 cells model
many Sox9 signaling pathways identified in primary murine
chondrocytes. FGF-1 and FGF-2 were found to increase
Sox9 mRNA levels and the corresponding activity of the
Sox9-dependent 48 bp Col2a1 enhancer reporter. This
may have relevance to the activity of chondrocytes attempt-
ing the repair of cartilage damage or when considering
strategies for therapeutic intervention. For example, Sox9
expression is elevated in the joints of mice attempting to
repair damage induced by the expression of a mutant type
IIA collagen gene35. In situ analysis showed that Sox9
expression corresponds with the most proliferative and
metabolically active chondrocytes present in the repair
tissue. Likewise, expression of endogenous FGF-2 is cor-
related with the repair of joint damage, as a neutralizing
antibody to FGF-2 blocks the repair of full-thickness carti-
lage defects in a rabbit model, while the infusion of FGF-2
leads to improved repair36. Thus, Sox9 provides a direct
link between the input of prochondrogenic growth factors
and the expression of chondrocytic genes needed for
repair.
We report the novel finding that FGF-9 stimulates Sox9
expression and activity in a human chondrocyte-like cell
line. In agreement with our findings, FGF-9 and FGF-2
were also found to be the most potent FGF family members
in stimulating growth and matrix production in chicken
chondrocyte cultures37. As mentioned previously, FGF-9
expression is associated with the growth of benign cartilage
nodules in the joints of chondromatosis patients. Taken
together with our results, stimulation of the FGF-9/FGFR/
Sox-9 signaling pathway may have therapeutic potential in
stimulating the repair of cartilage damage. However, further
studies are needed to define the full spectrum of FGF-9
biological functions. FGF-9 signals through both FGFR2c
and FGFR3b23, and mice lacking FGFR3 have severe
achondroplasia38. However, no defects in cartilage or
cartilage-derived tissues have been described for mice
lacking FGF-9, but XY sex reversal and lung hypoplasia
have been reported instead39,40. This suggests that addi-
tional FGFs can compensate for the loss of FGF-9 in
developing cartilage, but such functional redundancy does
not exist for FGFR3. The phenotypic similarity between the
FGF-9 and Sox9 deficiency and male sex reversal is
striking and raises the intriguing possibility that FGF-9/
Sox9 signaling is required for the normal development of
the male reproductive organs. The role of FGF-9 in repro-
ductive development needs to be considered when assess-
ing the therapeutic potential of FGF-9 for joint repair
approaches.
The repression of Col2 expression by IL-1β is not unique
to SW1353 cells and has been reported in immortalized
human chondrocyte cell lines18,41. However, we present
the original finding that SW1353 cells respond to increasing
IL-1β levels with dynamic range of responses. The func-
tional significance of this observation will depend on ad-
ditional studies. However, it is worth considering whether
stimulation of the 48 bp Col2a1 enhancer by low levels of
Fig. 5. The opposing effects of FGFs and cytokines on the
expression of Sox9 mRNA in SW1353 cells. RNA was isolated
from SW1353 cells treated for 48 h with vehicle (control), FGF-1
(200 ng/ml), FGF-2 (5.9 ng/ml), FGF-9 (200 ng/ml), TNFα (10 ng/
ml), or IL-1β (10 ng/ml) as indicated. Sox9 expression was
quantitated by Taqman and normalized to GAPDH expression.
Data represents the mean and standard error from two or more
experiments depending on the treatment group.
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IL-1 may relate to the paradoxical results from osteoarthritic
joints, where chondrocyte IL-1 expression correlates with
increased type II collagen synthesis30,32. In other words, do
chondrocytes express low levels of IL-1 in an attempt to
drive Col2 expression and stimulate repair?
In summary, we show that SW1353 cells conserve
many of the Sox9 signaling pathways described in studies
of murine chondrocytes. We extend these studies and
present the novel finding that FGF-9 is a potent factor in
regulating Sox9 expression and activity. We make the
novel observation that FGF-1, -2, and -9 can attenuate
or reverse Sox9 inhibition caused by pro-inflammatory
cytokines. Furthermore, we demonstrate that SW133 cells
react to increasing IL-1β levels with a dynamic range of
responses. Therefore, we consider SW1353 cells to be a
useful human cell model for studying Sox9 signaling
pathways.
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